- Home
- CRVS vs LGCB Comparison
CRVS vs LGCB Comparison
Compare CRVS & LGCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- LGCB
- Stock Information
- Founded
- CRVS 2014
- LGCB 2011
- Country
- CRVS United States
- LGCB Japan
- Employees
- CRVS N/A
- LGCB N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- LGCB
- Sector
- CRVS Health Care
- LGCB
- Exchange
- CRVS Nasdaq
- LGCB Nasdaq
- Market Cap
- CRVS 395.9M
- LGCB N/A
- IPO Year
- CRVS 2016
- LGCB 2023
- Fundamental
- Price
- CRVS $7.21
- LGCB $0.29
- Analyst Decision
- CRVS Buy
- LGCB
- Analyst Count
- CRVS 4
- LGCB 0
- Target Price
- CRVS $10.83
- LGCB N/A
- AVG Volume (30 Days)
- CRVS 519.3K
- LGCB 1.4M
- Earning Date
- CRVS 11-05-2024
- LGCB 11-15-2024
- Dividend Yield
- CRVS N/A
- LGCB N/A
- EPS Growth
- CRVS N/A
- LGCB N/A
- EPS
- CRVS N/A
- LGCB N/A
- Revenue
- CRVS N/A
- LGCB $8,500,375.00
- Revenue This Year
- CRVS N/A
- LGCB N/A
- Revenue Next Year
- CRVS N/A
- LGCB N/A
- P/E Ratio
- CRVS N/A
- LGCB N/A
- Revenue Growth
- CRVS N/A
- LGCB N/A
- 52 Week Low
- CRVS $1.05
- LGCB $0.25
- 52 Week High
- CRVS $7.54
- LGCB $5.71
- Technical
- Relative Strength Index (RSI)
- CRVS 74.25
- LGCB 21.65
- Support Level
- CRVS $6.30
- LGCB $0.25
- Resistance Level
- CRVS $6.98
- LGCB $0.38
- Average True Range (ATR)
- CRVS 0.48
- LGCB 0.04
- MACD
- CRVS 0.13
- LGCB 0.05
- Stochastic Oscillator
- CRVS 87.96
- LGCB 21.39
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).